Labiotech.eu

Startup Scout 9 Nov 2018

This Biotech Uses Radioactive Chemicals to Diagnose Brain Cancer

In Athens, Greece, we find pro-Actina. This biotech is working on a method to diagnose brain cancer by measuring how ‘leaky’ the brain is. Mission: Founded in 2006, the company is working to improve glioma diagnosis by using a combination of CT scans and an injectable radioactive chemical tracer. Gliomas are the most common forms […]

November 9, 2018 - 3 minutesmins - By Jonathan Smith

huntingtons epigenetics oxford biodynamics

News and Trends 8 Nov 2018

Epigenetics Test Can Distinguish Between Huntington’s Disease Stages

A study run by Oxford BioDynamics suggests that we could predict Huntington’s more easily by analyzing epigenetic changes in the patient’s DNA. Epigenetics describes the way that the expression of our genes is regulated, often influenced by environmental exposure, without changing the genetic code. Ways of modifying gene expression include attaching chemical groups to DNA […]

November 8, 2018 - 2 minutesmins - By Jonathan Smith

Claus Crone Fuglsang Novozymes Industrial Biotechnology Bioeconomy

Interview 8 Nov 2018

How Industrial Biotech is Opening the Way to the Bioeconomy

Biology is helping us find more sustainable solutions to the world’s problems. Claus Crone Fuglsang, Senior VP of Research and Technology at Novozymes, gave me an insight into the rapidly moving field of industrial biotech. Novozymes, the world’s largest producer of industrial enzymes, is one of the oldest players in the field of industrial biotech. […]

November 8, 2018 - 5 minutesmins - By Clara Rodríguez Fernández

Inside Labiotech 7 Nov 2018

What’s The Impact Of Labiotech On The Biotech Ecosystem? (Hint: It’s High … )

Our mission is to deliver the best content and to bring together people making up the biotech ecosystem in Europe. How do we do it? Is it actually impactful? If so, how? Let me try to answer… To start off, let’s take some perspective, what’s the current state of the connectivity of the biotech industry […]

November 7, 2018 - 3 minutesmins - By Philip Hemme

bone therapeutics bone disease hip header

News and Trends 7 Nov 2018

Belgian Biotech to Abandon Phase III Cell Therapy Trial for Bone Disease

Bone Therapeutics is going to discontinue its cell therapy Phase III trial after finding little hope of success for patients with the bone disease osteonecrosis. If all had gone as planned, the full trial would have monitored 118 patients over 24 months. However, an interim analysis on 44 patients after 12 months found little evidence […]

November 7, 2018 - 2 minutesmins - By Jonathan Smith

In Depth 7 Nov 2018

Biohacking: Democratization of Science or Just a Quirky Hobby?

The biohacking movement is making scientific research accessible to everyone under the form of low-cost community labs. What does it mean to be a biohacker and how is it changing the way we do science? Scientific research is undoubtedly an arduous endeavor. One that requires highly trained and skilled scientists and that can only be […]

November 7, 2018 - 5 minutesmins - By External Contributor

autoimmune liver disease Genkyotex organ

News and Trends 7 Nov 2018

Solid Phase II Performance for French Autoimmune Liver Disease Drug

Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial. Over six weeks, the drug reduced the blood levels of a liver disease biomarker molecule by up to 23% in 92 participants. In patients with late-stage disease, who have few treatments available, […]

November 7, 2018 - 2 minutesmins - By Jonathan Smith

chikungunya virus mosquito Themis bioscience

News and Trends 6 Nov 2018

First Potential Vaccine for Chikungunya Virus Flies Through Phase II

The mosquito-borne chikungunya virus may one day have a vaccine, as an Austrian biotech’s lead candidate gets positive results in Phase II. Themis Bioscience measured the blood levels of antibodies against the company’s vaccine in 263 healthy volunteers. Four weeks after injections of its lead candidate vaccine, the participants had produced antibodies to protect themselves […]

November 6, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 6 Nov 2018

Potential HIV Treatment Shows Early Stage Promise

According to Phase I/IIa trial results from an Israeli biotech, an HIV drug reduced patients’ HIV levels by up to 99%, and might one day become a new treatment for the infection. The trial, run by Zion Medical, found that the synthetic peptide drug reduced the level of viral RNA in patients’ blood by up to […]

November 6, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 5 Nov 2018

Series C Bags German Company €17M for Irregular Heartbeat Treatment

Omeicos Therapeutics has secured €17M in a Series C round to fund clinical development of its lead treatment for irregular heartbeat. Robert Fischer, CEO of the German biopharmaceutical company, told me that getting the attention of investors such as the Dutch company Forbion, which led the round, was just as helpful as the money itself. […]

November 5, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 5 Nov 2018

DNA Repair Treatment Shows Early Promise for Treating Cancer

Paris-based Onxeo has proved in humans the potential of a cancer treatment that interferes with DNA repair mechanisms. The therapy has potential to work in a wide range of tumors without cancer cells becoming resistant. Onxeo has reported preliminary results from an ongoing Phase I trial in which six different doses will be tested. […]

November 5, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2018

Gut Bacteria Treatment Shows Promise for Rare Genetic Kidney Condition

The Swedish biotech Oxthera reported positive preliminary Phase II results using its gut bacteria treatment, Oxabact, in patients with a rare genetic condition that causes kidney failure. The results came from an interim analysis one year into a three-year trial, where Oxthera is testing its gut microbiome treatment on patients with primary hyperoxaluria type […]

November 2, 2018 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

This Biotech Uses Radioactive Chemicals to Diagnose Brain Cancer

Epigenetics Test Can Distinguish Between Huntington’s Disease Stages

How Industrial Biotech is Opening the Way to the Bioeconomy

What’s The Impact Of Labiotech On The Biotech Ecosystem? (Hint: It’s High … )

Belgian Biotech to Abandon Phase III Cell Therapy Trial for Bone Disease

Biohacking: Democratization of Science or Just a Quirky Hobby?

Solid Phase II Performance for French Autoimmune Liver Disease Drug

First Potential Vaccine for Chikungunya Virus Flies Through Phase II

Potential HIV Treatment Shows Early Stage Promise

Series C Bags German Company €17M for Irregular Heartbeat Treatment

DNA Repair Treatment Shows Early Promise for Treating Cancer

Gut Bacteria Treatment Shows Promise for Rare Genetic Kidney Condition

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!